PPI-Gastric Cancer Link Remains After H. Pylori Eradication

Share this content:
 PPI use was correlated with elevated risk of gastric cancer even after H. pylori elimination, researchers found.
PPI use was correlated with elevated risk of gastric cancer even after H. pylori elimination, researchers found.

(HealthDay News) -- Long-term proton pump inhibitor (PPI) use is associated with increased risk of gastric cancer (GC) even after Helicobacter pylori (HP) eradication therapy, according to a study published online Oct. 31 in Gut.

Ka Shing Cheung, from the University of Hong Kong, and colleagues examined the correlation between PPI use and GC among HP-infected subjects who had received HP therapy. A total of 63,397 eligible subjects who had received an outpatient prescription of clarithromycin-based triple therapy between 2003 and 2012 were enrolled.

The researchers found that 0.24 percent of the subjects developed GC during a median follow-up of 7.6 years. PPI use was correlated with elevated risk of GC (hazard ratio, 2.44; 95 percent confidence interval, 1.42 to 4.2), while histamine-2 receptor antagonist use was not associated with increased risk (hazard ratio, 0.72; 95 percent confidence interval, 0.48 to 1.07). Duration of PPI use was correlated with increased risk (for ≥one, ≥two, and ≥three years, the hazard ratios were 5.04 [95 percent confidence interval, 1.23 to 20.61], 6.65 [95 percent confidence interval, 1.62 to 27.26], and 8.34 [95 percent confidence interval, 2.02 to 34.41], respectively). PPI versus non-PPI use was correlated with an adjusted absolute risk difference of 4.29 excess GCs per 10,000 person-years (95 percent confidence interval, 1.25 to 9.54)

"Long-term use of PPIs was still associated with an increased GC risk in subjects even after HP eradication therapy," the authors write.

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs